Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02954094 · ClinicalTrials.gov registry record

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

A clinical trial of Hepatocellular Cancer, sponsored by Target PharmaSolutions.

Active
Registry status
10,000
Enrollment target
20
Study locations

NCT02954094 is a study of Hepatocellular Cancer that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 10,000 participants, above the 317-participant average among 15 other Hepatocellular Cancer trials with a reported enrollment target (3055% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02954094, a study of Hepatocellular Cancer, is active but no longer recruiting, sponsored by Target PharmaSolutions.

ACTIVE NOT RECRUITING
Registry status
10,000 participants
Enrollment target
20
Study locations

Study Summary

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Conditions Studied

Hepatocellular Cancer

Study Locations (20)

California

  • University of Southern California/Norris Comprehensive Cancer Center - Los Angeles
  • Stanford University - Palo Alto
  • California Liver Research Institute - Pasadena
  • University of California-Davis - Sacramento
  • University of California - San Francisco

Florida

  • Gastro Florida - Clearwater
  • University of Florida Hepatology Research at CTRB - Gainesville
  • University of Florida Health Gastroenterology - Jacksonville
  • Schiff Center for Liver Diseases/University of Miami - Miami
  • Tampa General Medical Group - Tampa

Georgia

  • Piedmont Atlanta Hospital - Atlanta
  • Piedmont Cancer Institute - Atlanta
  • Emory University Hospital - Atlanta

Illinois

  • Northwestern University Division of Gastroenterology and Hepatology - Chicago
  • Rush University Medical Center - Chicago
  • University of Chicago - Chicago

Arizona

  • Banner University Medical Center - Phoenix

Arkansas

  • University of Arkansas - Little Rock

District of Columbia

  • Georgetown University - Washington D.C.

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2016-12
Est. Completion 2027-02

Sponsor

Target PharmaSolutions

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02954094

The ClinicalTrials.gov registry entry for NCT02954094 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 317-participant average among 15 other Hepatocellular Cancer trials with a reported enrollment target (3055% higher). The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02954094 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02954094 about?

NCT02954094 is a clinical study titled "A Longitudinal Observational Study of the Natural History and Management of Patients With HCC". TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectru...

What is the current status of trial NCT02954094?

This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2016-12. Estimated completion is 2027-02.

What conditions does trial NCT02954094 study?

This clinical trial studies the following conditions: Hepatocellular Cancer.

Who is sponsoring clinical trial NCT02954094?

This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02954094 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.